N-6-苯并噻唑基-乙酰胺 | 58249-63-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 中文名称: N-6-苯并噻唑基-乙酰胺
• 英文名称: N-acetyl-6-aminobenzothiazole
• 英文别名: 6-Acetamidobenzothiazol；6-Acetylamino-benzothiazol；6-Acetylamino-benzo<1,3>thiazol；6-acetamidobenzothiazole；N-benzothiazol-6-yl-acetamide；N-Benzothiazol-6-yl-acetamid；N-(1,3-benzothiazol-6-yl)acetamide
• CAS: 58249-63-1
• 化学式: C₉H₈N₂OS
• 分子量: 192.241
• InChiKey: ZJSLLQFUQDEFFC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  70.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-6-苯并噻唑基-乙酰胺 在 劳森试剂 作用下， 以 苯 为溶剂， 反应 5.0h， 以70%的产率得到6-thioacetamidobenzothiazole
  参考文献：
  名称：

  新型 2-取代噻唑并 [4,5-f] 异喹啉/喹啉和苯并 [1,2-d:4,3-d'] 双噻唑的合成及其作为 COX-1 和 COX-2 抑制剂的潜力

  摘要：

  2-取代的噻唑并[4,5-f]异喹啉、噻唑并[4,5-f]喹啉和苯并[1,2-d:4,3-d']双噻唑的高效、通用合成已由5硝基异喹啉完成/喹啉和 6-硝基苯并噻唑，所有产品均已通过光谱（IR、H 和 C NMR、LR/HR EI/FAB/ESI-MS）彻底鉴定。噻唑并[4,5-f]异喹啉的合成是此类杂芳烃的首次合成。对涵盖所有三种类型的 18 种化合物进行了 COX-1 和 COX-2 抑制筛选，其中一些表现出中等活性。

  DOI：

  10.3998/ark.5550190.0011.b22
• 作为产物：
  描述：

  6-硝基苯并噻唑 在 铁粉 、 溶剂黄146 作用下， 生成 N-6-苯并噻唑基-乙酰胺
  参考文献：
  名称：

  Petitcolas et al., Bulletin de la Societe Chimique de France, 1949, p. 103,111

  摘要：

  DOI：

文献信息

• Visible-light induced decarboxylative C2-alkylation of benzothiazoles with carboxylic acids under metal-free conditions
  作者：Bin Wang、Pinhua Li、Tao Miao、Long Zou、Lei Wang

  DOI：10.1039/c8ob02476f

  日期：——

  C2-alkylation of benzothiazoles with aliphatic carboxylic acids was disclosed. In the presence of an acridinium salt as a photocatalyst and air as an oxidant, a wide range of secondary or tertiary aliphatic carboxylic acids were employed as alkylation reagents, providing the desired products in good to excellent yields under mild reaction conditions with a broad substrate scope.

  公开了一种光氧化还原催化苯并噻唑与脂肪族羧酸的C 2-烷基化的有效方案。在存在cri啶盐作为光催化剂和空气作为氧化剂的情况下，广泛使用的仲或叔脂族羧酸作为烷基化试剂，可在温和的反应条件下以宽泛的底物范围提供所需的产物，收率良好至优异。
• Direct C–H Cyanoalkylation of Quinoxalin-2(1<i>H</i>)-ones via Radical C–C Bond Cleavage
  作者：Lin Yang、Pin Gao、Xin-Hua Duan、Yu-Rui Gu、Li−Na Guo

  DOI：10.1021/acs.orglett.7b03984

  日期：2018.2.16

  An efficient synthesis of cyanoalkylated heteroarenes via iron-catalyzed direct C–H cyanoalkylation of heteroarenes has been developed. Structurally diverse cyanoalkyl motifs generated through C–C bond cleavage of cyclobutanone oxime esters have been introduced into quinoxalin-2(1H)-ones, flavone, benzothiazoles, and caffeine in good to excellent yields. Remarkably, less-strained cyclopentanone and

  通过铁催化杂芳烃的直接CH氰基氰基化反应，可以有效地合成氰基烷基化的杂芳烃。通过环丁酮肟酯的C–C键裂解产生的结构多样的氰基烷基基序已以良好的优异产率引入到喹喔啉-2（1 H）-酮，黄酮，苯并噻唑和咖啡因中。显着地，在该氰基烷基化反应中，较少应变的环戊酮和未应变的环己酮肟酯也是合适的底物。
• NOVEL IMIDAZOPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER
  申请人：DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION

  公开号：US20190315738A1

  公开（公告）日：2019-10-17

  The present invention relates to a novel imidazopyridine derivative, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient for preventing or treating cancer. The novel imidazopyridine derivative according to the present invention, a stereoisomer thereof and a pharmaceutically acceptable salt thereof can effectively inhibit cancer-related kinases, are excellent in inhibiting proliferation of cancer cells in a cancer cell line, and effectively inhibit proliferation of cancer cells (cancer cell apoptosis) in a cancer cell heterograft model, and thus can be useful as a pharmaceutical composition containing the same as an active ingredient for preventing or treating cancer. Also, the novel imidazopyridine derivative according to the present invention, the stereoisomer thereof, and the pharmaceutically acceptable salt thereof can effectively inhibit Src and Fyn, thereby being useful as a pharmaceutical composition for preventing or treating the Src and Fyn related diseases, and in particular, have been confirmed to be useful in diabetic nephropathy in animal model experiments. Therefore, the compound of the present invention can be effective as a pharmaceutical composition containing the same as an active ingredient for preventing or treating diabetic nephropathy.

  本发明涉及一种新的咪唑吡啶衍生物，一种制备该衍生物的方法，以及含有该衍生物作为活性成分用于预防或治疗癌症的药物组合物。根据本发明的新的咪唑吡啶衍生物及其立体异构体和药学上可接受的盐可以有效抑制与癌症相关的激酶，在癌细胞系中抑制癌细胞增殖方面表现出优异，有效抑制癌细胞在癌细胞异种移植模型中的增殖（癌细胞凋亡），因此可以作为含有该衍生物作为活性成分的药物组合物用于预防或治疗癌症。此外，根据本发明的新的咪唑吡啶衍生物、其立体异构体和药学上可接受的盐可以有效抑制Src和Fyn，因此可用作预防或治疗与Src和Fyn相关疾病的药物组合物，特别在动物模型实验中已确认在糖尿病肾病中有用。因此，本发明的化合物可以作为含有该衍生物作为活性成分的药物组合物，有效预防或治疗糖尿病肾病。
• [EN] INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION<br/>[FR] INHIBITEURS DE LA REPLICATION DU VIRUS DE L'IMMUNODEFICIENCE HUMAINE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2010130034A1

  公开（公告）日：2010-11-18

  Compounds of formula I wherein a, R1, R2, R3, R4, R5 and R6 are defined herein, are useful as inhibitors of HIV replication.

  式I中的化合物，其中a、R1、R2、R3、R4、R5和R6如本文所定义，可用作HIV复制抑制剂。
• Imidazopyridine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for preventing or treating cancer
  申请人：DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION

  公开号：US10870647B2

  公开（公告）日：2020-12-22

  The present invention relates to a novel imidazopyridine derivative, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient for preventing or treating cancer. The novel imidazopyridine derivative according to the present invention, a stereoisomer thereof and a pharmaceutically acceptable salt thereof can effectively inhibit cancer-related kinases, are excellent in inhibiting proliferation of cancer cells in a cancer cell line, and effectively inhibit proliferation of cancer cells (cancer cell apoptosis) in a cancer cell heterograft model, and thus can be useful as a pharmaceutical composition containing the same as an active ingredient for preventing or treating cancer. Also, the novel imidazopyridine derivative according to the present invention, the stereoisomer thereof, and the pharmaceutically acceptable salt thereof can effectively inhibit Src and Fyn, thereby being useful as a pharmaceutical composition for preventing or treating the Src and Fyn related diseases, and in particular, have been confirmed to be useful in diabetic nephropathy in animal model experiments. Therefore, the compound of the present invention can be effective as a pharmaceutical composition containing the same as an active ingredient for preventing or treating diabetic nephropathy.

  本发明涉及一种新型咪唑吡啶衍生物、其制备方法以及一种含有该衍生物作为有效成分的预防或治疗癌症的药物组合物。根据本发明的新型咪唑吡啶衍生物、其立体异构体和其药学上可接受的盐可有效抑制癌症相关激酶，在抑制癌细胞系中的癌细胞增殖方面表现出色，并可有效抑制癌细胞异种移植模型中的癌细胞增殖（癌细胞凋亡），因此可作为含有其作为活性成分的药物组合物用于预防或治疗癌症。 另外，根据本发明的新型咪唑吡啶衍生物、其立体异构体及其药学上可接受的盐可以有效抑制 Src 和 Fyn，从而可作为药物组合物用于预防或治疗与 Src 和 Fyn 相关的疾病，特别是已在动物模型实验中证实可用于糖尿病肾病。因此，本发明的化合物作为一种含有相同活性成分的药物组合物，可有效预防或治疗糖尿病肾病。

表征谱图